Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 8/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.43 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | KDM4A | O75164 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | LATS1 | O95835 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23478663 | 1.00 | SMN1; SMN2 (0.48) | SMN1; SMN2NAMPTCYP2C9CACNA1HCACNA1B | |
| SCHEMBL19964841 | 0.90 | SMN1; SMN2 (0.45) | SMN1; SMN2NAMPTCACNA1HCACNA1BCACNA1C | |
| SCHEMBL30387402 | 0.87 | F2 (0.54) | SMN1; SMN2NAMPTCYP2C9F2CYP3A4 | |
| SCHEMBL23478384 | 0.87 | F2 (0.54) | SMN1; SMN2NAMPTCYP2C9F2CYP3A4 | |
| SCHEMBL28593575 | 0.87 | F2 (0.54) | SMN1; SMN2NAMPTCYP2C9F2CYP3A4 | |
| Trifluoroacetic Acid SCHEMBL30632844 | 0.83 | F2 (0.53) | NAMPTF2 | |
| SCHEMBL30469092 | 0.82 | KDM4A (0.54) | SMN1; SMN2CACNA1HCACNA1BCACNA1CKDM4A | |
| SCHEMBL25677972 | 0.82 | KDM4A (0.54) | SMN1; SMN2CACNA1HCACNA1BCACNA1CKDM4A | |
| SCHEMBL30765591 | 0.82 | NAMPT (0.48) | SMN1; SMN2NAMPTCYP2C9F2 | |
| SCHEMBL30759309 | 0.81 | CACNA1H (0.46) | SMN1; SMN2NAMPTCACNA1HCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2025-12-02 | — | — | US | disclosed |
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2024-03-21 | — | — | US | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486278-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | SMN1; SMN2 1476/4885NAMPT 1282/4885CYP2C9 4847/4885 |
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | SMN1; SMN2 1476/4885NAMPT 1282/4885CYP2C9 4847/4885 |
| US-20240092788-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SMN1; SMN2 1476/4885NAMPT 1282/4885CYP2C9 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.